Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Dentsply Sirona downgrade details — to Mkt Perform at Barrington Research (62.68)Barrington Research downgrades XRAY to Mkt Perform from Outperform noting co generated $996.5 million in rev for Q4, below firm's est of $1.02 billion and the consensus est of $1.01 billion. Constant currency growth for the combined businesses (DENTSPLY and SIRONA) was 4.3%. Internal rev growth was 1.8%. The internal growth result includes the negative impact of a channel inventory reduction due to the change in relationship between the company and Patterson (<strong>PDCO</strong> — NOT RATED). Firm admits that, while they like what XRAY is doing to position itself for the longer term, they think that both the very modest and lower earnings growth now expected in 2017 (along with the back-end loaded nature of it) and their reduced EPS expectations through 2019 will likely put a nearterm cap on share price appreciation for at least the next couple of quarters.</td> </tr></table>"